 |
|
|
| |
Polypharmacy and prevalence of multiple drug-drug interactions
in hepatitis C patients treated with pangenotypic direct-acting antivirals:
an analysis from three European countries
|
| |
| |
EASL 2022 June 22-26 London
FRANK TACKE,1 JUAN TURNES,2 ANDREAS HINTZ,3 STEFANO FAGIUOLI,4 ANTONI SICRAS,5 TIM UMLAND,3 LUCA DEGLI
ESPOSTI,6 RAMON MORILLO,7 ANTONIO GARCIA HEROLA,8 MEHTAP GUNDOGDU,9 MARINELA MENDEZ,10 GEMA ALVAREZ NIETO,11
KIM VANSTRAELEN,12 CANDIDO HERNANDEZ,12 ALESSANDRA MANGIA13
1CharitE - Universitatsmedizin Berlin, Berlin, Germany; 2. Complejo Hospitalario Universitario de Pontevedra, Gastroenterology and Hepatology, Spain; 3. Alexander Apotheke, Hamburg, Germany; 4. ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 5. Atrys health, HEOR, Barcelona, Spain; 6. Clicon S.r.l., Health Economics and Outcomes Research, Ravenna, Italy; 7. Hospital Universitario de Valme, Hospital Pharmacy, Sevilla, Spain; 8. Hospital Marina Baixa, Villajoyosa, Spain; 9. Gilead Sciences GmbH, Medical Affairs, München, Germany; 10. Gilead Sciences S.L., Medical Affairs, Madrid, Spain; 11. Gilead Sciences S.r.l, Medical Affairs, Milan, Italy; 12. Gilead Sciences, Global Medical Affairs, United Kingdom;13. Fondazione "Casa Sollievo della Sofferenza" IRCCS, San Giovanni Rotondo, Italy
|
| |
|
|
|
|
|
